



Agenda Item No:

12

Report to:	Humber and North Yorkshire Integrated Care Board
Date of Meeting:	10 January 2024
Subject:	Clinical & Professional Update
Director Sponsor:	Dr Nigel Wells, Executive Director for Clinical & Professional
Author:	Dr Nigel Wells, Executive Director for Clinical & Professional

STATUS OF THE REPORT:

Approve Discuss Assurance Information A Regulatory Requirement

SUMMARY OF REPORT:

This report provides a summary of prevalence of Cardiovascular disease (CVD) across the populations of HNY ICS and the work taking place by the CVD Prevention and Detection programme to tackle this. There is also an update on the newly adopted Medical Retinal Drugs policy, the steps being taken to implement it and challenges the system need to address.

RECOMMENDATIONS:

Members are asked to:

- i) Note the prevalence of CVD across our populations, the health inequality gap and the work taking place to address this.
- ii) Note the newly agreed commissioning policy for medical retinal drugs, the potential challenges being worked through and next steps for implementation.

ICB STRATEGIC OBJECTIVE

Managing Today	<input checked="" type="checkbox"/>
Managing Tomorrow	<input checked="" type="checkbox"/>
Enabling the Effective Operation of the Organisation	<input type="checkbox"/>

IMPLICATIONS

Finance	The ICB's system Ophthalmology costs are the second highest in England (all costs); the new medical retinal drug policy advocates using the lowest cost treatment option, where this is clinically appropriate.
---------	---

Quality	Quality aspects of new policies are identified through completion of an Integrated Impact Assessment prior to the policy being approved.
HR	None identified
Legal / Regulatory	None identified
Data Protection / IG	None identified
Health inequality / equality	The CVD prevention programme update describes the task and finish group to focus on coastal areas due to health inequalities.
Conflict of Interest Aspects	Conflict of Interests are captured and managed at the Clinical & Professional Executive Committee as part of the regular, standing agenda.
Sustainability	None identified

ASSESSED RISK:

Risks will be identified and assessed for individual workstreams within this update and will inform the proposed recommendations and decision-making. All risks will then be monitored by the Clinical & Professional Executive Committee.

MONITORING AND ASSURANCE:

Recommendations will be monitored by the Clinical & Professional Executive Committee.

ENGAGEMENT:

The development of the Medical Retinal Drug policy has been widely engaged upon – including at the Clinical and Professional Group, System Ethics Group, Clinical and Professional Executive Committee and the System Eye Care Group.

REPORT EXEMPT FROM PUBLIC DISCLOSURE

No Yes

If yes, please detail the specific grounds for exemption.